Today, AstraZeneca PLC (LON:AZN) announced that its drugs Lynparza (olaparib) and Imfinzi (durvalumab) have received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the treatment of certain advanced or recurrent endometrial cancers. This recommendation is based on the DUO-E Phase III clinical trial results, which demonstrated a significant improvement in progression-free survival compared to chemotherapy alone.
The CHMP's opinion is specifically directed at two patient groups based on mismatch repair (MMR) status. For patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer, the combination of Imfinzi plus chemotherapy followed by Lynparza and Imfinzi has been recommended. Meanwhile, for those with mismatch repair deficient (dMMR) disease, the recommendation is for Imfinzi plus chemotherapy followed by Imfinzi alone.
The DUO-E Phase III trial, published in October 2023, indicated that the combination therapy reduced the risk of disease progression or death by 43% for pMMR patients and by 58% for dMMR patients, compared to the control group.
Endometrial cancer is the fourth most common cancer among women in Europe, with nearly 125,000 new cases and over 30,000 deaths in 2022. The survival rate for early-stage diagnosis is high, but for advanced stages, it drops significantly, highlighting an urgent need for new treatments, particularly for the 70-80% of patients with pMMR disease.
Els Van Nieuwenhuysen, a trial investigator, emphasized the importance of this recommendation for improving outcomes in Europe, especially for patients with pMMR disease who have limited treatment options. Susan Galbraith of AstraZeneca (NASDAQ:AZN) also noted the potential benefits of combining Lynparza and Imfinzi for these patients.
Regulatory submissions for Imfinzi and Lynparza are under review in Japan and other countries, and Imfinzi plus chemotherapy has recently been approved in the US for dMMR patients with primary advanced or recurrent endometrial cancer.
The safety profiles of the treatment regimens were considered manageable and consistent with the known profiles of the individual agents. This development represents a potential new treatment option for endometrial cancer patients in Europe, pending final approval.
In other recent news, AstraZeneca's IMFINZI (durvalumab) has shown significant improvements in event-free and overall survival for patients with muscle-invasive bladder cancer (MIBC) in the NIAGARA Phase III trial. This development is a potential game-changer in the treatment of MIBC. The drug has also received FDA approval for treating adults with advanced or recurrent endometrial cancer that is mismatch repair deficient.
In the executive realm, AstraZeneca's CEO, Pascal Soriot, transferred a significant number of shares to family members, a personal financial planning activity. Analyst firms Citi, BMO Capital, and Deutsche Bank have maintained positive ratings on AstraZeneca's shares due to these recent developments.
These are the latest updates in AstraZeneca's journey.
InvestingPro Insights
The recent positive recommendation from the European Medicines Agency for AstraZeneca's cancer drugs Lynparza and Imfinzi could be a significant step forward for the company, as it looks to expand its oncology portfolio. With AstraZeneca's market capitalization standing at a robust $242.03 billion, the company's financial strength seems well-aligned with its innovative drive. According to InvestingPro, net income for AstraZeneca is expected to grow this year, and two analysts have revised their earnings upwards for the upcoming period, signaling confidence in the company's financial prospects.
While the company is trading at a high P/E ratio of 38.11, indicating a premium valuation, its revenue growth over the last twelve months of 8.6% reflects a healthy expansion in its business. Moreover, AstraZeneca has been a prominent player in the Pharmaceuticals industry and has maintained dividend payments for 32 consecutive years, which could be appealing to income-focused investors. For those interested in further insights, there are additional 16 InvestingPro Tips available, which can be accessed with a special offer using the coupon code PRONEWS24 for an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.